Karyopharm Therapeutics Inc (KPTI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Karyopharm Therapeutics Inc (KPTI) has a cash flow conversion efficiency ratio of 0.040x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-11.83 Million) by net assets ($-292.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See KPTI net asset quality index to measure how much of total assets are equity-financed.
Karyopharm Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Karyopharm Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Karyopharm Therapeutics Inc (KPTI) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Karyopharm Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Karyopharm Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BANXA HOLDINGS INC.
F:AC00
|
N/A |
|
HPQ SILICON INC.
F:O08
|
-0.051x |
|
Mirae Asset Global REIT Co. Ltd.
KO:396690
|
-0.005x |
|
Surapon Foods Public Company Limited
BK:SSF
|
0.082x |
|
Arianne Phosphate Inc
V:DAN
|
-0.019x |
|
Woongjin Thinkbig Co Ltd
KO:095720
|
0.019x |
|
Sangsangin Ian No.1 Special Purpose Acquisition Co. Ltd
KQ:307870
|
-0.030x |
|
Union Petrochemical Public Company Limited
BK:UKEM
|
0.032x |
Annual Cash Flow Conversion Efficiency for Karyopharm Therapeutics Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Karyopharm Therapeutics Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Karyopharm Therapeutics Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-292.93 Million | $-75.37 Million | 0.257x | -62.46% |
| 2024-12-31 | $-186.02 Million | $-127.49 Million | 0.685x | +0.67% |
| 2023-12-31 | $-136.21 Million | $-92.72 Million | 0.681x | -92.42% |
| 2022-12-31 | $-16.66 Million | $-149.55 Million | 8.979x | +567.86% |
| 2021-12-31 | $-79.67 Million | $-107.12 Million | 1.344x | +142.41% |
| 2020-12-31 | $50.55 Million | $-160.23 Million | -3.170x | +17.31% |
| 2019-12-31 | $49.77 Million | $-190.82 Million | -3.834x | -341.33% |
| 2018-12-31 | $183.17 Million | $-159.12 Million | -0.869x | -52.56% |
| 2017-12-31 | $129.46 Million | $-73.72 Million | -0.569x | -9.47% |
| 2016-12-31 | $162.24 Million | $-84.39 Million | -0.520x | -9.73% |
| 2015-12-31 | $198.37 Million | $-94.03 Million | -0.474x | -90.53% |
| 2014-12-31 | $206.79 Million | $-51.45 Million | -0.249x | -27.25% |
| 2013-12-31 | $154.93 Million | $-30.29 Million | -0.196x | -135.14% |
| 2012-12-31 | $-27.88 Million | $-15.51 Million | 0.556x | -17.67% |
| 2011-12-31 | $-12.65 Million | $-8.55 Million | 0.676x | -- |
About Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exporti… Read more